Microbiotica reported positive Phase Ib data for MB‑310, an orally administered live biotherapeutic for ulcerative colitis: 12 of 19 treated patients achieved clinical remission versus 3 of 10 on placebo. Responders sustained remission during a three‑month follow‑up and showed histologic and mucosal marker improvements, the company said. MB‑310 is an orally delivered consortium of live bacteria intended to modulate the gut microbiome and mucosal immunity; live biotherapeutics are defined by regulatory frameworks as biological products containing live organisms. The result supports continued development and larger trials to confirm durability and safety.